M. Schlichting

2.0k total citations · 1 hit paper
22 papers, 1.3k citations indexed

About

M. Schlichting is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, M. Schlichting has authored 22 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 4 papers in Surgery. Recurrent topics in M. Schlichting's work include Colorectal Cancer Treatments and Studies (11 papers), Lung Cancer Treatments and Mutations (7 papers) and Radiomics and Machine Learning in Medical Imaging (4 papers). M. Schlichting is often cited by papers focused on Colorectal Cancer Treatments and Studies (11 papers), Lung Cancer Treatments and Mutations (7 papers) and Radiomics and Machine Learning in Medical Imaging (4 papers). M. Schlichting collaborates with scholars based in Germany, United States and France. M. Schlichting's co-authors include Carsten Bokemeyer, İ. Çelik, Filippo de Braud, J.T. Hartmann, Igor Bondarenko, P. Koralewski, Gunter Schuch, Angela Zubel, S Arnaud and E. Paris and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and Osteoporosis International.

In The Last Decade

M. Schlichting

20 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study

2011 612 citations Carsten Bokemeyer, Igor Bondarenko et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M. Schlichting Germany	9	847	604	374	296	241	22	1.3k
M. Nicholson United Kingdom	7	456 0.5×	171 0.3×	400 1.1×	154 0.5×	38 0.2×	10	873
Laura Rocci Italy	13	809 1.0×	41 0.1×	223 0.6×	291 1.0×	37 0.2×	17	1.0k
Jorge L. González-Calvin Spain	16	156 0.2×	121 0.2×	31 0.1×	291 1.0×	182 0.8×	22	814
Shohei Yoshiya Japan	20	423 0.5×	77 0.1×	253 0.7×	13 0.0×	619 2.6×	94	1.4k
Çağatay Arslan Türkiye	19	437 0.5×	80 0.1×	273 0.7×	27 0.1×	18 0.1×	96	924
Filipa Macedo Portugal	11	579 0.7×	95 0.2×	361 1.0×	52 0.2×	11 0.0×	21	1.1k
Kyoung Ha Kim South Korea	17	325 0.4×	163 0.3×	240 0.6×	8 0.0×	120 0.5×	72	932
K. Wakai Japan	14	388 0.5×	188 0.3×	173 0.5×	12 0.0×	20 0.1×	18	988
Giovanni Orsolini Italy	21	190 0.2×	145 0.2×	67 0.2×	288 1.0×	12 0.0×	82	1.3k
Renate Schaberl-Moser Austria	14	986 1.2×	92 0.2×	200 0.5×	14 0.0×	62 0.3×	23	1.2k

Countries citing papers authored by M. Schlichting

Since Specialization

Citations

This map shows the geographic impact of M. Schlichting's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Schlichting with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Schlichting more than expected).

Fields of papers citing papers by M. Schlichting

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M. Schlichting. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Schlichting. The network helps show where M. Schlichting may publish in the future.

Co-authorship network of co-authors of M. Schlichting

This figure shows the co-authorship network connecting the top 25 collaborators of M. Schlichting. A scholar is included among the top collaborators of M. Schlichting based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M. Schlichting. M. Schlichting is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ivanyi, Philipp, et al.. (2023). 358MO Quality-adjusted life-year and life-year estimates for patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the combined positive score 1-19 subgroup treated with pembrolizumab +/- chemotherapy vs cetuximab-containing regimens. Annals of Oncology. 34. S1609–S1609. 1 indexed citations

Ivanyi, Philipp, et al.. (2023). EE359 Cost-Effectiveness of Pembrolizumab + Chemotherapy Versus Cetuximab-Containing Regimens ‘Extreme’ and ‘TPEx’, for R/M SCCHN Patients with a CPS between 1 and 19, in Italy. Value in Health. 26(12). S120–S120.

D’Angelo, Sandra P., et al.. (2019). Health-related quality of life in patients with metastatic Merkel cell carcinoma receiving second-line or later avelumab treatment: 36-month follow-up data. Annals of Oncology. 30. v538–v538. 1 indexed citations

D’Angelo, Sandra P., et al.. (2018). Responder analysis based on patient-reported outcomes (PROs) and clinical endpoints (CEPs) in patients (pts) with metastatic Merkel cell carcinoma (mMCC) treated with avelumab. Annals of Oncology. 29. viii457–viii458. 1 indexed citations

Reck, Martin, James Chih‐Hsin Yang, Pieter E. Postmus, et al.. (2017). JAVELIN Lung 100: updated design of a phase 3 trial of avelumab vs platinum doublet chemotherapy as first-line (1L) treatment for metastatic or recurrent PD-L1+ non-small-cell lung cancer (NSCLC). Annals of Oncology. 28. v492–v492. 5 indexed citations

Bharmal, Murtuza, Paul Williams, M. Schlichting, et al.. (2017). Health-related quality of life (HRQoL) in patients (Pts) with Merkel cell carcinoma (MCC) receiving avelumab. Annals of Oncology. 28. xi23–xi23.

Patel, Manish R., John Ellerton, Manish Agrawal, et al.. (2016). Avelumab (MSB0010718C; anti-PD-L1) in patients with metastatic urothelial carcinoma progressed after platinum-based therapy or platinum ineligible. Annals of Oncology. 27. vi267–vi267. 18 indexed citations

Piessevaux, Hubert, E. Van Cutsem, Carsten Bokemeyer, et al.. (2012). Early Tumor Shrinkage and Clinical Outcome in Metastatic Colorectal Cancer: Analysis of Predictive Utility in the CRYSTAL and OPUS Studies. Annals of Oncology. 23. xi37–xi37. 1 indexed citations

Bokemeyer, Carsten, Igor Bondarenko, J.T. Hartmann, et al.. (2011). Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. Annals of Oncology. 22(7). 1535–1546. 612 indexed citations breakdown →

10.

Tejpar, Sabine, Carsten Bokemeyer, İ. Çelik, et al.. (2011). Influence of KRAS G13D mutations on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy with or without cetuximab.. Journal of Clinical Oncology. 29(15_suppl). 3511–3511. 37 indexed citations

11.

Piessevaux, Hubert, Carsten Bokemeyer, M. Schlichting, S. Heeger, & Sabine Tejpar. (2011). Impact of early tumor shrinkage on long-term outcome in metastatic colorectal cancer (mCRC) treated with FOLFOX4 with or without cetuximab: Lessons from the OPUS trial.. Journal of Clinical Oncology. 29(4_suppl). 398–398. 11 indexed citations

12.

Piessevaux, Hubert, Eric Van Cutsem, C. Bokemeyer, et al.. (2011). Early tumor shrinkage and long-term outcome in metastatic colorectal cancer (mCRC): Assessment of predictive utility across treatment arms in the CRYSTAL and OPUS studies.. Journal of Clinical Oncology. 29(15_suppl). 3572–3572. 8 indexed citations

13.

Tejpar, Sabine, Carsten Bokemeyer, İ. Çelik, M. Schlichting, & Eric Van Cutsem. (2011). The role of the KRAS G13D mutation in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy plus cetuximab.. Journal of Clinical Oncology. 29(4_suppl). 630–630. 1 indexed citations

14.

Bokemeyer, Carsten, Claus Henning Köhne, P. Rougier, et al.. (2010). Cetuximab with chemotherapy (CT) as first-line treatment for metastatic colorectal cancer (mCRC): Analysis of the CRYSTAL and OPUS studies according to KRAS and BRAF mutation status.. Journal of Clinical Oncology. 28(15_suppl). 3506–3506. 65 indexed citations

15.

Piessevaux, Hubert, Marc Buyse, Wendy De Roock, et al.. (2009). Radiological tumor size decrease at week 6 is a potent predictor of outcome in chemorefractory metastatic colorectal cancer treated with cetuximab (BOND trial). Annals of Oncology. 20(8). 1375–1382. 63 indexed citations

16.

Cutsem, Eric Van, István Láng, G D’Haens, et al.. (2008). The crystal study: Assessment of the predictive value of KRAS status on clinical outcome in patients with mcrc receiving first-line treatment with cetuximab or cetuximab plus folfiri. Annals of Oncology. 19. 17–17. 11 indexed citations

17.

Sobrero, Alberto, Werner Scheithauer, Joan Maurel, et al.. (2005). Cetuximab plus irinotecan for metastatic colorectal cancer (mCRC): Safety analysis of the first 400 patients in a randomized phase III trial (EPIC). Journal of Clinical Oncology. 23(16_suppl). 3580–3580. 6 indexed citations

18.

Schlichting, M., et al.. (2003). Male-Pattern Baldness Is Common in Men with X-Linked Recessive Ichthyosis. Dermatology. 207(3). 308–309. 5 indexed citations

19.

Chapuy, M. C., Raymond Pamphile, E. Paris, et al.. (2002). Combined Calcium and Vitamin D3 Supplementation in Elderly Women: Confirmation of Reversal of Secondary Hyperparathyroidism and Hip Fracture Risk: The Decalyos II Study. Osteoporosis International. 13(3). 257–264. 409 indexed citations

20.

Schlichting, M., Roy Sanders, & Michael J. Gardner. (1956). The blood picture of 200 Thoroughbreds.. Veterinary medicine. 51. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact